Drugs / Trimodulin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04576728 | Oct 2020 → Jun 2021 | COVID-19 | Biotest | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT05722938 | Sep 2023 → Jul 2028 expected | pneumonia | Biotest | Recruiting | No outcome recorded |
| Phase 3 | NCT05531149 | Dec 2022 → May 2025 | COVID-19, acute respiratory distress syndrome, bacterial pneumonia, fungal lung infectious disease +1 | Biotest | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimodulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05531149 ↗ |
| Modality | Protein / enzyme biologic | “Trimodulin (human polyvalent immunoglobulin [Ig] M ~ 23%, IgA ~ 21%, IgG ~ 56% preparation)” PMID 39138518 ↗ Aug 2024 |
| Route | Intravenous | “intravenous (IV) administration” NCT04576728 ↗ |